CIS-DIAMMINEDICHLOROPLATINUM(II) THERAPY FOR ADVANCED OVARIAN-CANCER

Google Scholar
  • 1 January 1980
    • journal article
    • research article
    • Vol. 64  (10-1) , 1147-1148
Abstract
Eleven of 32 patients (34%) with advanced ovarian cancer previously treated with conventional therapies had partial or complete responses to 5 day courses of cis-diamminedichloroplatinum(II) (CDDP) (20 mg/m2 per day), with 9 showing objective response prior to initiation of the 2nd course. Median duration of response was 6 mo. (range, 2-18+). Response to CDDP was not correlated with age, pathologic subtype, tumor grade or bulk disease but was correlated with response to prior treatment. Eight of 15 patients previously responsive to single alkylating agents or cyclophosphamide plus doxorubicin (adriamycin) responded to CDDP. Response to CDDP was observed in only 3 of 17 patients showing no response to this prior chemotherapy. The highest response rate to CDDP was seen in that subset of patients sensitive to cyclophosphamide and doxorubicin (7 of 10 patients).